8 results about "Human rotavirus" patented technology

A single-domain antibody (sdAb) which binds to head domain of VP6 derived from a human rotavirus A and has neutralization activity against different the rotavirus A types.

The invention relates to the technical field of rotaviruses, in particular to a G8P [8] type group A rotavirus CZ-23 and application thereof. The invention relates to a G8P [8] type group A rotavirus CZ-23, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 11, 2023, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number is CGMCC (China General Microbiological Culture Collection Center) The invention provides a novel human rotavirus wild strain which is reported and separated for the first time in China, and the strain is strong in virus replication capability and good in hereditary stability, can be applied to development of vaccine strains of human rotavirus vaccines, and is suitable for attenuated rotavirus oral vaccines.

The present invention provides a human-ovine rotavirus recombinant plasmid, a human-ovine rotavirus reassortant virus strain, and a construction method and application thereof, belonging to the technical field of rotavirus vaccines. The sequences of 8 human rotavirus infectious clone plasmids of the present invention are respectively shown as SEQ ID NO:1 to SEQ ID NO:8. By using the above 8 human rotavirus plasmids and 11 ovine rotavirus infectious clone plasmids, 8 human-ovine rotavirus reassortant strains were successfully prepared through a reverse genetics virus rescue system, filling the gap that the main antigens of existing rotavirus vaccine strains in China do not match the main epidemic strains in China.

The invention belongs to the technical field of medical biology, and particularly relates to a circular RNA (Ribonucleic Acid) molecule and an application thereof in resisting rotavirus replication, and provides the circular RNA molecule of which the nucleotide sequence is shown as SEQ ID No.1. Through a high-throughput sequencing technology, a human rotavirus wild strain obtained by separation is infected with a host cell and then is subjected to complete transcription sequencing, so that a high-throughput sequencing result is obtained. A brand-new circular RNA molecule circRNA46 for regulating and controlling rotavirus proliferation is found, the nucleotide sequence of the circular RNA molecule circRNA46 is shown as SEQ ID No.1, the circRNA46 is up-regulated after virus infection, overexpression of the circRNA46 can obviously inhibit virus replication, and the circRNA46 has the effect of resisting rotavirus proliferation.

The invention discloses a human rotavirus strain and a method for separating, culturing and identifying the human rotavirus strain, the human rotavirus strain is a rotavirus RV009 strain, the human rotavirus strain is submitted to China General Microbiological Culture Collection Center (CGMCC) on July 22, 2024, and the preservation number is CGMCC No.45999. The invention also discloses a method for separating, culturing and identifying the human rotavirus strain. The separation, culture and identification method of the human rotavirus strain RV009 provided by the invention is beneficial to rapid virus amplification, production cycle shortening and low-cost obtaining of high-yield viruses, and is beneficial to vaccine production, virology research and development of diagnostic reagents.

The invention discloses a recombinant human rotavirus vaccine and a preparation method thereof, and relates to the technical field of vaccines, the vaccine comprises: (1) antigens: 25-65 [mu] g of P [4] type antigen, 25-65 [mu] g of P [6] type antigen and 25-65 [mu] g of P [8] type antigen, and the amino acid sequences of the P [4] type antigen, the P [6] type antigen and the P [8] type antigen are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; the active component of each type of antigen is a recombinant rotavirus VP8 fusion protein, the recombinant rotavirus VP8 fusion protein is composed of a first polypeptide, a second polypeptide and a third polypeptide, the first polypeptide is a truncated human rotavirus VP8 protein, the second polypeptide is a truncated human rotavirus VP8 protein, and the third polypeptide is a truncated human rotavirus VP8 protein. The second polypeptide is an Fc fragment amino acid sequence of immunoglobulin IgG4; the third polypeptide is not charged or negatively charged; (2) an adjuvant: 4.0 mg to 6.0 mg of an aluminum hydroxide adjuvant; and (3) buffer solution: sodium chloride and HEPES solution. The recombinant human rotavirus vaccine is effective and safe.

The present invention discloses a human G9 rotavirus HN‑28 strain, which is Reoviridae / Rotavirus A / Human rotavirus (G9P8) HN‑28 Strain, and has been deposited in the China Center for Type Culture Collection on January 13, 2022, with a deposit number of CCTCC NO: V202203. RNA‑PAGE shows that the electrophoresis type of the virus strain is long, and the 11 bands present a unique electrophoresis pattern of group A rotavirus in a 4:2:3:2 arrangement; the whole genome second-generation sequencing results show that this strain is a G9P[8] rotavirus. The present invention successfully isolates a G9 rotavirus wild strain that can be stably propagated through the isolation, culture and cloning and purification of rotavirus-positive fecal samples, named HN‑28 strain, which can be used to prepare rotavirus vaccines.

The invention provides a preparation and optimization method of a purified stock solution of a human rotavirus, relates to the technical field of viral vaccines, and provides a human rotavirus production method which comprises the following steps: S1, carrying out primary recovery on Vero cells; s2, carrying out subculture on the Vero cells; s3, infecting the Vero cells with rotavirus; s4, harvesting cultured viruses; s5, clarifying a virus harvest; s6, after clarification, supernate is taken for ultrafiltration; s7, virus purification after ultrafiltration, an optimized production scheme is provided for large-scale production, a phosphate buffer solution containing poloxamer is added during culture virus harvesting, a purification medium in the virus purification process is limited, most of impurities such as host protein and DNA are removed, and the yield is increased. The purification process is applied to preparation of the oral rotavirus attenuated live vaccine for the first time in China, the safety of the vaccine is greatly improved, meanwhile, the production method is suitable for large-scale production, and the production efficiency is improved.